NASDAQ:HOOK - Hookipa Pharma Stock Price, Forecast & News

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Hookipa Pharma Inc (NASDAQ:HOOK) issued its earnings results on Tuesday, November, 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.66) by $0.21. The firm had revenue of $2.04 million for the quarter, compared to analysts' expectations of $2.35 million. View Hookipa Pharma's Earnings History.

Hookipa Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Hookipa Pharma.

5 equities research analysts have issued 12-month target prices for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 57.5% from the stock's current price. View Analyst Price Targets for Hookipa Pharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hookipa Pharma.

Headlines about HOOK stock have trended extremely negative on Sunday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hookipa Pharma earned a news impact score of -4.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Hookipa Pharma.

Hookipa Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 297,700 shares, an increase of 213.4% from the December 31st total of 95,000 shares. Based on an average daily trading volume, of 90,600 shares, the short-interest ratio is currently 3.3 days. Approximately 2.6% of the shares of the company are sold short. View Hookipa Pharma's Current Options Chain.

Some companies that are related to Hookipa Pharma include Dermira (DERM), NextCure (NXTC), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), XBiotech (XBIT), Odonate Therapeutics (ODT), RAPT Therapeutics (RAPT), Phathom Pharmaceuticals (PHAT), Applied Therapeutics (APLT), Gossamer Bio (GOSS), Radius Health (RDUS), Achillion Pharmaceuticals (ACHN), G1 Therapeutics (GTHX) and Stoke Therapeutics (STOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), AT&T (T), Exxon Mobil (XOM), Gossamer Bio (GOSS), Axsome Therapeutics (AXSM), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Dominion Energy (D), Marathon Petroleum (MPC) and Pfizer (PFE).

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HOOK stock can currently be purchased for approximately $12.06.

Hookipa Pharma has a market capitalization of $260.38 million. Hookipa Pharma employs 56 workers across the globe.View Additional Information About Hookipa Pharma.

The official website for Hookipa Pharma is http://www.hookipapharma.com/.

Hookipa Pharma's mailing address is 350 Fifth Avenue 72nd Floor Suite 7240, New York NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]